Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic fever. The virus is endemic in over 120 countries, causing over 350 million infections per year.
Dengue vaccine development is challenging because of the need to induce simultaneous protection against four antigenically distinct DENV serotypes and evidence that, under some conditions, vaccination can enhance disease due to specific immunity to the virus. While several live-attenuated tetravalent dengue virus vaccines display partial efficacy, it has been challenging to induce balanced protective immunity to all 4 serotypes. Instead of using whole-virus formulations, we are exploring the potentials for a particulate subunit vaccine, based on DENV E-protein displayed on nanoparticles that have been precisely molded using Particle Replication in Non-wetting Template (PRINT) technology.
Here we describe immunization studies with a DENV2-nanoparticle vaccine candidate. The ectodomain of DENV2-E protein was expressed as a secreted recombinant protein (sRecE), purified and adsorbed to poly (lactic-co-glycolic acid) (PLGA) nanoparticles of different sizes and shape. We show that PRINT nanoparticle adsorbed sRecE without any adjuvant induces higher IgG titers and a more potent DENV2-specific neutralizing antibody response compared to the soluble sRecE protein alone. Antigen trafficking indicate that PRINT nanoparticle display of sRecE prolongs the bio-availability of the antigen in the draining lymph nodes by creating an antigen depot. Our results demonstrate that PRINT nanoparticles are a promising platform for delivering subunit vaccines against flaviviruses such as dengue and Zika.
Author Summary
Dengue virus (DENV) is transmitted by mosquitoes and is endemic in over 120 countries, causing over 350 million infections yearly. Most infections are clinically unapparent, but under specific conditions, dengue can cause severe and lethal disease. DENV has 4 distinct serotypes and secondary DENV infections are associated with hemorrhagic fever and dengue shock syndrome. This enhancement of infection complicates vaccine development and makes it necessary to induce protective immunity against all 4 serotypes. Since whole virus vaccine candidates struggle to induce protective immunity, we are developing a nanoparticle display vaccine approach. We have expressed, purified and characterized a soluble recombinant E-protein (sRecE). Regardless of nanoparticle shape or size, particulation of sRecE enhances DENV specific IgG titers and induces a robust, long lasting neutralizing antibody response and by adsorbing sRecE to the nanoparticles, we prolong the exposure of sRecE to the immune system.
Nanoparticle display shows great promise in dengue vaccine development and possibly other mosquito-borne viruses like zika virus.
The Latest on: Nanoparticle vaccines
[google_news title=”” keyword=”Nanoparticle vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Nanoparticle vaccines
- New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruseson April 17, 2024 at 7:41 pm
Researchers at Georgia Tech and the University of Wisconsin have created a broad-spectrum vaccine capable of defending against various SARS-CoV-2 variants and related bat coronaviruses.
- Novavax gets grant for coronavirus spike proteins for stable and immunogenic vaccineson April 17, 2024 at 5:34 am
Discover how Novavax Inc's patent for coronavirus Spike proteins & nanoparticles in vaccines enhances immunogenicity & protects against SARS-CoV-2.
- Curevac gets grant for composition for covid-19 mRNA vaccine in lipid nanoparticleon April 17, 2024 at 5:34 am
Discover Curevac NV's groundbreaking patent for a composition targeting SARS-CoV-2 with mRNA and lipid nanoparticles. Learn about stabilizing mutations and substitutions in the spike protein sequence ...
- Nanoparticle News and Researchon April 16, 2024 at 5:01 pm
Study explores nanoparticle-enhanced curcumin formulations ... and Harvard have created a vaccine that can induce a strong antibody response against SARS-CoV-2. A team of scientists at the ...
- How can companies address consumers who are averse to products using a novel technology?on April 16, 2024 at 12:08 pm
Researchers from IE Business School and Indian Institute of Management Shillong have published a new study that examines why certain consumers are averse to products using a novel technology and what ...
- Pfizer, BioNTech Get Legal Pause in Moderna’s COVID-19 Vaccine Patent Lawsuiton April 16, 2024 at 5:54 am
A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged patent infringement related to their COVID-19 vaccine Comirnaty.
- Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine developmenton April 16, 2024 at 5:00 am
Chimeron Bio, a Philadelphia-headquartered biotech company, has received a 2024 National Institutes of Health's Small Business Innovation Research Innovative Concept Award through the National Cancer ...
- New vaccine strategy may mean the end of the line for endless boosterson April 14, 2024 at 5:00 pm
Scientists at UC Riverside have demonstrated a new, RNA-based vaccine strategy that is effective against any strain of a virus and can be used safely even by babies or the immunocompromised.
- COVID Vaccines Are Not Linked to Sudden Cardiac Death in Young Adults, CDC Study Findson April 12, 2024 at 10:51 am
A new study from the CDC states that there is no data to support an association between the COVID vaccines and sudden cardiac death among previously healthy young persons Vanessa Etienne is an ...
via Bing News